Additionally, degradation of SREBP1 coupled with suppression of SREBP1-mediated lipogenesis was demonstrated to impact the response of EGFR mutant NSCLC cells to Osimertinib [135]. This evidence concerns the gene SREBF1 and non-small cell lung carcinoma.